22nd Century Group (XXII) Acquires GVB Biopharma
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- S&P 500, Dow rise as AI boost counters US-Iran tensions
- Oil rises, as US-Iran strikes risk limiting already impaired supplies
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
GVB Biopharma Acquisition "Adds Scale, Scope and Diversification" - Dawson James Bullish on 22nd Century Group (XXII) with $8.50 Price Target
May 16, 2022 8:14 AM EDTDawson James analyst James McILree reiterated a Buy rating and $8.50 price target on 22nd Century Group (NASDAQ: XXII), following the company's announcement it had acquired GVB Biopharma.
The analyst comments: "22nd Century announced the acquisition of GVB Biopharma, one of the largest producers of... More
